论文部分内容阅读
最近几十年,在癌症的研究中,利用人体自身的免疫系统来对抗癌细胞是当前肿瘤研究的热点,免疫疗法备受关注,并被寄予了很大的希望。其中,T细胞是特异性免疫系统的代表,其免疫效果强烈,且特异性强,近几年,免疫肿瘤学的关注焦点基本都集中在T细胞上。近期,基于T细胞的免疫疗法取得重大进展。7月12日,美国食品和药品监督管理局(FDA)下属肿瘤药物咨询委员会(ODAC)以10︰0的投票确定了一种嵌合
In recent decades, in cancer research, the use of the body’s own immune system to fight cancer cells is a hot topic in cancer research. Immunotherapy has drawn great attention and great hopes have been placed. Among them, T cells are the representatives of the specific immune system, its strong immune effect, and specificity, in recent years, the basic focus of immune oncology are concentrated in T cells. Recently, significant progress has been made in T cell-based immunotherapy. July 12, the US Food and Drug Administration (FDA) oncology drug Advisory Committee (ODAC) voted 10: 0 to determine a chimeric